Login to Your Account

Conatus: Phase II results 'portal' to bigger success, maybe road to NASHville

By Randy Osborne
Staff Writer

Thursday, September 24, 2015
Investors wanted but didn't get details from Conatus Pharmaceuticals Inc. about next clinical moves, though the firm offered color Thursday on positive phase II data disclosed the previous day with emricasan, an oral pan-caspase inhibitor, in severe portal hypertension (PH) with cirrhosis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription